Organization
Yale Cancer Center
38 abstracts
1 poster
Abstract
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Medical Oncology, Yale School of Medicine, Yale Cancer Center, Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Phase II trial of pembrolizumab in patients with brain metastases.Org: Massachusetts General Hospital and Harvard Medical School, Dana-Farber Cancer Institute, Dana-Farber/Brigham and Women's Cancer Center, Massachusetts General Hospital, Yale University,
Abstract
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.Org: Cleveland Clinic Lerner College of Medicine, University of California San Diego, Yale Cancer Center, University of California, San Francisco Medical Center, Stanford University School of Medicine, Division of Oncology,
Abstract
Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.Org: Weill Cornell Medicine, Mount Sinai Hospital-Breast Medical Oncology, Massachusetts General Hospital, UM/Sylvester Comprehensive Cancer Center, UNC Patient Advocates for Research Council,
Abstract
Diversity, equity, & inclusion (DEI) and health equity (HE) education in hematology/oncology (HO) fellowship: A longitudinal curriculum.Org: Yale Cancer Center, Yale School of Medicine,
Abstract
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, Cancer Research and Biostatistics, University of Kansas Medical Center, ASCO,
Abstract
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.Org: Yale Cancer Center, Yale School of Medicine, Emory University School of Medicine, Nashville Breast Center, Dallas Surgical Group,
Abstract
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).Org: Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Université Paris-Sud, Université Paris-Saclay, Netherlands Cancer Institute,
Abstract
Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group,
Abstract
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.Org: Dana-Farber Cancer Institute, Yale School of Medicine, University of Pittsburgh Medical Center (UPMC), Yale Cancer Center, Harvard Medical School,
Abstract
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).Org: Yale New Haven Hospital, New Haven, CT, Upstate University Hospital, Syracuse, NY, SUNY Upstate University Hospital,
Abstract
Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine,
Abstract
Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer.Org: Yale Cancer Center, Yale School of Medicine, University of Witwatersrand Faculty of Health Sciences, University of Miami Health System, University Witwatersrand Faculty Health Sciences,
Abstract
Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.Org: Dana-Farber Cancer Institute, 4D Path Inc., Vanderbilt University Medical Center, University of Pittsburgh, O'Neal Comprehensive Cancer Center at UAB,
Abstract
Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale University School of Medicine, Bioinformatics Support Program,
Abstract
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.Org: University of Chicago Medicine, University of Chicago, University of California, San Francisco Department of Medicine, University of California, San Francisco Department of Surgery, University of California, San Francisco,
Abstract
Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, DFCI/PCC Fellowship Program - Attendings, Personalis, Inc.,
Abstract
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.Org: Dana-Farber Cancer Institute/Harvard Medical School, Mayo Clinic, Department of Biostatistics & Data Science, The University of North Carolina at Chapel Hill, The University of Texas MD Anderson Cancer Center,
Abstract
Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.Org: Yale School of Medicine, Mayo Clinic, Oncology Center of Excellence, U.S. Food and Drug Administration, Cancer Outcomes, Public Policy and Effectiveness Research Center,
Abstract
Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study.Org: Mayo Clinic, U.S. Food and Drug Administration, Yale University, Fight Colorectal Cancer, Arlington, VA, CancerHacker Lab,
Abstract
A new model to enhance enrollment of diverse participants to therapeutic clinical trials.Org: Golgi, Inc, Lexington, KY, Boston, MA, Yale Cancer Center, Yale School of Medicine,
Abstract
PD-L1, tumor mutational burden (TMB) and long-term survival in patients with non-small cell lung cancer (NSCLC) and brain metastases.Org: Brigham and Women's Hospital, Yale Cancer Center, Brigham and Women's Hospital/Dana-Farber Cancer Institute,
Abstract
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.Org: KSQ Therapeutics, Cambridge, MA, Roche Pharma Research and Early Development, Roche Innovation Center, Dana-Farber Cancer Institute, Hackensack University Medical Center,
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine, University of Washington School of Medicine, Massachusetts General Hospital, Harvard Medical School, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).Org: Cancer Research @UCC, Cork, Ireland, Lineberger Comprehensive Center, Chapel Hill, NC, University of California, San Francisco, CA, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD,
Abstract
Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.Org: Yale School of Medicine, Yale Cancer Center,
Abstract
Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC).Org: Yale Cancer Center, Foundation Medicine, Inc., Cambridge, MA, Perlmutter Cancer Center, NYU Langone Health,
Abstract
ERBB2 mutations and association with molecular phenotype in urothelial carcinoma.Org: Dana-Farber Cancer Institute, Yale University School of Medicine, Yale School of Medicine, Yale Cancer Center, Yale University,
Abstract
Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).Org: Dana-Farber Cancer Institute, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center, Yale Cancer Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.Org: Berry Consultants, LLC, Seagen, Cleveland Clinic Taussig Cancer Instititute, Yale School of Medicine, University of California Irvine,
Abstract
Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, DFCI/PCC Fellowship Program - Attendings, Yale Cancer Center,
Abstract
Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Yale Cancer Center, Yale School of Medicine,
Abstract
Evaluation of the genomic and immune profiles of patients with lung adenosquamous carcinoma (LUAS) and association of response to treatment.Org: Caris Life Sciences, Irving, TX, The Warren Alpert Medical School of Brown University, Columbia University Irving Medical Center, New York, NY, USA, Yale Cancer Center, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
Associations between violence, distress, and cancer in transgender and non-transgender people.Org: Yale Cancer Center, University of Rochester Medical Center, James P. Wilmot Cancer Center - Pluta, Columbia University - Mailman School of Public Health, Emory University, Atlanta, GA, USA,
Abstract
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.Org: Yale School of Medicine, Yale Cancer Center, Yale University, University Hospital Leipzig, Cancer Center IRCCS Humanitas Research Hospital,
Abstract
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.Org: Exact Sciences Corporation, Cancer Research and Biostatistics (CRAB), Seattle, WA, ASCO, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Loyola University Chicago Stritch School of Medicine,
Abstract
Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.Org: Yale New Haven Hospital, Yale Cancer Center, Stanford Hospital and Clinics, Campus Bio Medico University of Rome, MedStar Health/Georgetown University Hospital,